期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

非小细胞肺癌诱导化疗后肿瘤体积变化规律及其影响因素 被引量：6

下载PDF
导出
摘要 目的通过分析非小细胞肺癌(NSCLC)化疗后肿瘤体积变化规律及可能影响其变化的相关因素,为诱导化疗的最佳周期数选择及放射治疗的最佳介入时机提供参考依据。方法以行过诱导化疗的首诊NSCLC患者为研究对象。使用TPS自带体积测量软件及ImageJ图像处理软件测量肿瘤体积,分析诱导化疗不同周期后的体积变化情况,并分析可能的影响因素:性别、年龄、肺癌大体分型、肿瘤所在部位、肿瘤病理类型、T分期,化疗前肿瘤体积。结果 (1)共有135例NSCLC患者入组,化疗前和化疗1、2、3、4、5、6周期后的肿瘤绝对体积分别为52 379.25(22 165.31,115 795.95)、42 734.88(16 882.68,84 586.18)、39 809.06(13 362.51,96 306.07)、28 880.07(11 077.05,72 422.28)、25 396.16(13 847.83,62 965.18)、30 753.01(12 092.30,60 979.18)和19 334.10(9 079.41,61 411.08)mm3。化疗前和1周期后绝对体积之间差异有统计学意义(Z=-6.100,P<0.001),两组的相对体积(假定化疗前肿瘤体积为1)差异也有统计学意义(Z=-5.843,P<0.001);化疗4周期和5周期后绝对体积差异有统计学意义(t=-2.023,P=0.049)。(2)logistic回归分析发现:T分期(2=3.901,P=0.048,OR=2.410)和原始体积大小(2=6.478,P=0.011,OR=0.538)分别为化疗1周期后肿瘤退缩率的独立影响因素。原始体积较大组较原始体积较小组的第1周期肿瘤退缩率相对较好,而T1～2组较T3～4组的第1周期肿瘤退缩率相对较好。结论 NSCLC诱导化疗可能1周期最佳;T分期和原始肿瘤体积大小是化疗第1周期后肿瘤退缩率的独立影响因素;建议诱导化疗1周期后即行放疗或同步放化疗。
作者 张纬建 邹喜 洪金省 陈群 石琴 郭飞宝
机构地区 福建医科大学附属第一医院放疗科 福建省福州市肺科医院肿瘤科
出处 《广东医学》 CAS CSCD 北大核心 2013年第11期1741-1744,共4页 Guangdong Medical Journal
关键词 非小细胞肺癌 肿瘤体积 诱导化疗 因素分析
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献16

  • 1JEMAL A,BRAY F,CENTER M M,Global cancer statistics [J].CA Cancer J Clin, 2011,61(2) : 69 - 90.
  • 2RIVERA M P. Multimodality therapy in the treatment of lung cancer[J]. Semin Respir Crit Care Med, 2004 , 25( Suppl 1) : 3-10.
  • 3WERNER WASIK M,XIAO Y, PEQUIGNOT E,et al. Assess-ment of lung cancer response after nonoperative therapy : tumor di-ameter ,bidimensional product, and volume. A serial CT scan ~based study[ J ]. Int J Radiat Oncol Biol Phys, 2001,51(1):56-61.
  • 4REDDY S P, HONG R L,NAGDA S, et al. Effect of tumor bulkon local control and survival of patients with T1 glottic cancer : a30 - year experience[ J]. Int J Radiat Oncol Biol Phys,2007,69(5): 1389 -1394.
  • 5WILLNER J, BAIER K,CARAGIANI E, et al. Dose, volume,and tumor control prediction in primary radiotherapy of non 一 small -cell lung cancer[ J]. Int J Radiat Oncol Biol Phys,2002,52(2):382 -389.
  • 6ALEXANDER B M,OTHUS M, CAGLAR HB, et al. Tumor vol-ume is a prognostic factor in non - small - cell lung cancer treatedwith chemoradiotherapy[ J]. Int J Radiat Oncol Biol Phys, 2011,79(5) : 1381 -1387.
  • 7BRITTON K R, STARKSCHALL G, TUCKER S L, et al. Assess-ment of gross tumor volume regression and motion changes during ra-diotherapy for non - small - cell lung cancer as measured by four -dimensional computed tomography [ J ]. Int J Radiat Oncol BiolPhys,2007,68(4) : 1036 ~ 1046.
  • 8EISENHAUERA E A, THERASSEB P, BOGAERTSC J, et al.New response evaluation criteria in solid tumours : revised RECISTguideline (version 1. 1 ) [ J]. Eur J Cancer,2009,45(2) : 228 -247.
  • 9韩宇,王岩,徐建明,刘烈军,赵传华,李志强,刘建芝,邱卉.诱导化疗后吉非替尼维持治疗晚期非小细胞肺癌的临床研究[J].临床肿瘤学杂志,2009,14(2):118-122. 被引量：12
  • 10KOUMARIANOU A, FOUNTZILAS G,KOSMIDIS P, et al. Nonsmall cell lung cancer in the elderly : clinico - pathologic,manage-ment and outcome characteristics in comparison to younger patients[J]. J Chemother, 2009, 21(5) : 573 -583.

二级参考文献22

  • 1张智慧,吴萍.晚期肺癌化疗的现状和未来[J].四川肿瘤防治,2004,17(4):264-267. 被引量：9
  • 2欧阳学农,余宗阳,陈樟树,李捷.局部晚期非小细胞肺癌预后因素评估[J].实用癌症杂志,2005,20(3):286-289. 被引量：7
  • 3游捷,施志明,韩宝惠,丁金芳.采用国际生存质量量表评价肺积方治疗非小细胞肺癌患者生存质量[J].中国中西医结合杂志,2006,26(1):33-37. 被引量：32
  • 4Scagliotti GV, Parikh P, yon Pawel J, et al. Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non- small-cell lung cancer [ J]. J Clin Oneol, 2008, 26:3543 -3551.
  • 5Han JY, Lee DH, Song JE, et al. Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer[J]. Cancer, 2008,113:388 - 395.
  • 6Mencoboni M, Bergaglio M, Serra M, et al. Maintenance therapy with gefitinib after first - line chemotherapy in patients affected by advanced non - small cell lung cancer [ J ]. Anticancer Res, 2007,27:4425 -4429.
  • 7Kelly K, Chansky K, Gaspar LE, et al. Phase Ⅲ trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage Ⅲ non - small - cell lung cancer: SWOG S0023 [ J ]. J Clin Oncol, 2008,26:2450 - 2456.
  • 8Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase Ⅲ trial[J]. Lung Cancer,2006, 52:155 - 163.
  • 9Fidias PM, Dakhil SR, Lyss AP, et al. Phase Ⅲ Study of Immediate Compared With Delayed Docetaxel After Front - Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non - Small -Cell Lung Cancer[J]. J Clin Oncol, 2009,27 (4):591 -598.
  • 10Xu JM, Han Y, Li YM, et at. Phase Ⅱ trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non - small - cell lung cancer [J]. BMC Cancer, 2006,16:288.

共引文献17

同被引文献49

  • 1Panmier A,Le Pechoux C. Radiotherapy in small cell lung cancer: where should it go[J]. Lung Cancer,2010,6(2) :133 - 140.
  • 2Reddy SP, Hong RL, Nagda S, et al. Effect oftumor bulk on local control and survival of patients with T1 glottic cancer:a 30 -year ex- perience[J]. Int J Radiat Oncoi Biol Phys,2007,69(5) :1389 -1394.
  • 3Alexander BM, Othus M, Caglarh HB, et al. Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemora- diotherapy[ J]. Int J Radiat Oncol Biol Phys ,201 1,79 ( 5 ) : 1381 - 1387.
  • 4Brade AM,Tannock IF. Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer: Repopulation as a cause of- treatment failure [ J ]. J Clin Oncol, 2006,24 ( 7 ) : 1020 - 1022.
  • 5E1 Sharouni SY,Kal ttB,Barten-Van Rijbroek A,et al. Concurrent versus sequential chemotherapy and radiotherapy inlimited disease small cell lung cancer:a retrospective comparative study[ J ]. Anti- cancer Res,2009,29 ( 12 ) :5219 - 5224.
  • 6Stinchcombe TE, Gore EM. Limitedstage small cell lung caneer:cur- rent chemoradiotherapy treatment paradigms[ J ]. Oncologlst,2010, 15(2) :187 - 195.
  • 7Ho QT, Kuo CJ. Vascular endothelial growth factor:biology and ther- apeutic applications[ J]. Int J Biochem Cell Biol,2007,39( 7/8): 1349 - 1357.
  • 8Mitsiades N,Yu WH,Poulaki V,et al. Matrixmetailoproteinase - 7 - mediated cleavage of fas ligand protects tumor cells from chemothera- peutic drug cytotoxicity [ J ]. Cancer Res,2009,61 ( 2 ) :577 - 581.
  • 9Stenvold H,Donnem T,Andersen S, et al. Overexpression of matrix metalloproteinase -7 and -9 in NSCLC tumor and stromalcells:cor- relation with a favorable clinical outcome[ J]. Lung Cancer,2012, 75(2) :235 -241.
  • 10Duffaud F,Therasse P. New guide|ines to evaluate the response to treatment in solid tumors[J]. Bull Cancer, 2000,87(12) : 881-886.

引证文献6

二级引证文献32

广东医学
2013年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部